Logo
x

Search

Subscribe Now

Migraine

Pfizer Signs a Commercialization Arrangement with Biohaven for Rimegepant to Treat Migraine

Pfizer Signs a Commercialization Arrangement with Biohaven for Rimegepant to Treat Migraine

  • November 10, 2021
Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine

Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine

  • November 9, 2021
AbbVie's Qulipta (atogepant) Receives the US FDA's Approval for the Treatment of Migraine

AbbVie's Qulipta (atogepant) Receives the US FDA's Approval for the Treatment of Migraine

  • September 29, 2021
Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine

Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine

  • September 7, 2021
AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM

AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM

  • August 19, 2021
Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA

Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA

  • June 16, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.